Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. - He, Chaoneng; Mi, Xiufang; Xu, Gaoqi; Xu, Xinglu; Xin, Wenxiu; Zhong, Like; Zhu, Junfeng; Shu, Qi; Fang, Luo; Ding, Haiying (PLoS ONE, 2024)